



ASX ANNOUNCEMENT

R&D TAX REBATE RECEIVED TALLING \$3.15 MILLION

- Actinogen receives R&D Tax Incentive rebate of \$3.15m
- Helps fund expanded Xanamem development program
- Further strengthens capital position following earlier successful \$16.5m capital raise
- Excellent progress made with global Alzheimer's trial XanADu – 159 patients enrolled, only 15 more patients required to complete enrolment

Sydney, 10 October 2018. Actinogen Medical (ASX: ACW) is pleased to advise that the Company has received an R&D Tax Incentive rebate of \$3.15 million for the 2017/2018 financial year.


Following Actinogen Medical's successful capital raising of \$16.5m in July, receipt of this rebate further adds to the Company's strong capital reserves. This financial position allows the Company to expand and strengthen the Xanamem development program and to value-add to the Xanamem data set.

CEO of Actinogen Medical, Dr Bill Ketelbey commented: "Receipt of this R&D rebate is well timed with our team continuing to make excellent progress with recruitment into our Alzheimer's study, XanADu. We have 159 patients enrolled, and only 15 more patients to go to complete enrolment of this important global study.

In addition to the ongoing funding of the XanADu study, our strong financial position greatly assists our broader Xanamem development plans to enhance the data set and to ultimately strengthen discussions with future development partners. We look forward to updating the market on these activities in due course."

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, is enrolling 174 patients at 25 research sites across Australia, the UK and the USA. Enrolment is expected to complete in Q4 2018, with top-line results expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.